Miceli R, et al. - In this post hoc analysis, researchers focused on the prognostic role of microsatellite instability (MSI) in radically resected gastric cancer (GC) patients randomized to XP (capecitabine/cisplatin) or XPRT. They analyzed 393 tissue samples, with 35 (9%) being MSI-high. Older age, Borrmann classification 1–2, antral localization, T3–4 stage, and intestinal type characterized this subgroup. A trend toward a worse prognosis was demonstrated by the microsatellite-stable subgroup vs the MSI-high group in univariable analysis: 3-year disease-free survival (DFS) was 76.3 vs 85.4%; 3-year overall survival (OS) was 81.7 vs 91.4%. It was confirmed in both DFS and OS in multivariable analyses. Overall, findings revealed an association of MSI-high status with specific clinical-pathological characteristics as well as with a trend toward better outcomes of Asian GC patients.